Projektin yksityiskohdat
Yleistajuinen kuvaus
Abdominal area cancers caused 43% of all cancer deaths in Finland in 2018. Colorectal cancer occurs progressively in young individuals, and many upper GI tract cancers, such as gastric and pancreatic cancers remain fatal, with major implications to the utilization of molecular medicine to unravel the characteristics of the carcinogenesis.
Modern 3D tumors models such as organoids enable patient-specific, cost-efficient, and moderate-throughput recapitulation of each tumor. Advances in organoid media conditions have made it possible to simultaneously alter several signaling routes mandatory for cancer growth. With the current technology, success rate of 70–90% in organoid establishment is feasible, and expansion to characterization takes place in weeks, providing a window of opportunity to patient-specific drug sensitivity testing of the model within a clinical time frame before initiating adjuvant chemotherapy.
We aim to improve and utilize precision medicine methods in the multidisciplinary management of abdominal cancers. By combining novel state of the art methods, circulating cell free tumor DNA (ctDNA) and organoids, into a prospective study with massive tissue acquisition, tumor profiling, and monitoring clinical course, we will be able to take the last steps of the applicability into clinical use, before moving on to clinical routine. By establishing a living organoid biobank, we can answer some of the most difficult questions in gastrointestinal tract carcinogenesis, and drive the bench research to focus on molecular aspects of a wide variety of deadly abdominal cancers.
Modern 3D tumors models such as organoids enable patient-specific, cost-efficient, and moderate-throughput recapitulation of each tumor. Advances in organoid media conditions have made it possible to simultaneously alter several signaling routes mandatory for cancer growth. With the current technology, success rate of 70–90% in organoid establishment is feasible, and expansion to characterization takes place in weeks, providing a window of opportunity to patient-specific drug sensitivity testing of the model within a clinical time frame before initiating adjuvant chemotherapy.
We aim to improve and utilize precision medicine methods in the multidisciplinary management of abdominal cancers. By combining novel state of the art methods, circulating cell free tumor DNA (ctDNA) and organoids, into a prospective study with massive tissue acquisition, tumor profiling, and monitoring clinical course, we will be able to take the last steps of the applicability into clinical use, before moving on to clinical routine. By establishing a living organoid biobank, we can answer some of the most difficult questions in gastrointestinal tract carcinogenesis, and drive the bench research to focus on molecular aspects of a wide variety of deadly abdominal cancers.
| Lyhennetty nimi | Pan-cancer organoid biobank for precision medicine in abdominal cancer |
|---|---|
| Akronyymi | PANORG |
| Tila | Käynnissä |
| Todellinen alku/loppupvm | 01/01/2021 → 31/12/2025 |